A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Cell cycle progression is tightly regulated by checkpoint mechanisms that verify cellular conditions before allowing passage to the next phase. Cyclin-CDK complexes act as molecular switches, activating or inactivating cell cycle machinery at specific transitions. Key checkpoints include: the G1 restriction point (is the cell large enough, is DNA undamaged?), the G2/M checkpoint (is DNA fully replicated?), and the spindle assembly checkpoint (are all chromosomes attached to spindle fibers?). Tumor suppressor proteins (p53, Rb) enforce these checkpoints; mutations that disable checkpoints contribute to uncontrolled cell division and cancer.
Map each checkpoint to its molecular sensors and effectors. Understand p53 as a 'guardian of the genome' that can halt the cycle or trigger apoptosis. Connect Rb protein inactivation to why cells pass the G1 checkpoint inappropriately in many cancers.
From the cell cycle overview, you know the basic sequence: G1 (growth), S (DNA synthesis), G2 (preparation), and M (mitosis). But what prevents a cell from racing through these phases recklessly — replicating damaged DNA, dividing before chromosomes are properly attached, or growing when the body doesn't need more cells? The answer is a system of molecular brakes and accelerators built from two families of proteins: cyclins and cyclin-dependent kinases (CDKs).
CDKs are protein kinases — enzymes that phosphorylate target proteins to activate or inactivate them. But CDKs are catalytically inactive on their own. They require a cyclin partner to switch on. Different cyclins are synthesized and destroyed at different phases of the cell cycle, creating waves of cyclin-CDK activity. Cyclin D-CDK4/6 drives progression through G1. Cyclin E-CDK2 triggers the G1/S transition and DNA replication origin licensing. Cyclin A-CDK2 operates during S phase. Cyclin B-CDK1 (also called MPF, maturation-promoting factor) drives entry into mitosis. The key principle is that cyclin levels oscillate — they rise through synthesis and fall through ubiquitin-mediated proteolysis — while CDK protein levels remain relatively constant. This means cell cycle progression is controlled by regulated protein destruction, not just by turning genes on.
Superimposed on this cyclin-CDK engine are checkpoints — surveillance mechanisms that halt progression if something is wrong. The G1 restriction point integrates growth factor signals and DNA damage status. If DNA is damaged, the tumor suppressor p53 is stabilized and activates transcription of the CDK inhibitor p21, which blocks cyclin-CDK complexes and arrests the cell in G1, buying time for repair or triggering apoptosis if damage is irreparable. The retinoblastoma protein (Rb) acts as a second gatekeeper: in its hypophosphorylated state, Rb sequesters the transcription factor E2F, preventing expression of S-phase genes. Only when cyclin D-CDK4/6 and then cyclin E-CDK2 progressively phosphorylate Rb does E2F get released, committing the cell to S phase. The G2/M checkpoint verifies that DNA replication is complete and undamaged before allowing entry into mitosis. The spindle assembly checkpoint ensures all chromosomes are properly attached to the mitotic spindle before anaphase proceeds.
Cancer, at its molecular core, is a disease of cell cycle deregulation. Mutations that constitutively activate cyclins or CDKs (oncogenes) or inactivate checkpoint proteins like p53 and Rb (tumor suppressors) remove the brakes on proliferation. But a single mutation is rarely sufficient — the multi-hit hypothesis holds that cancer typically requires mutations in multiple regulatory genes, which is why cancer incidence increases with age as mutations accumulate. Understanding the cyclin-CDK-checkpoint framework gives you the mechanistic vocabulary to interpret how specific mutations drive specific cancers and why targeted cancer therapies (like CDK4/6 inhibitors) work by reinstating the controls that tumor cells have lost.